Bristol-Myers Squibb Company PFD CONV 2 Profit Margin

The latest profit margin for BMYMP is 18.46% as of September 2026. That compares with 12.57% in the prior-year period — up 46.9% year over year. That is above the Healthcare sector average of 9.48%. Investors often review this figure alongside Bristol-Myers Squibb Company PFD CONV 2's historical trend and sector peers before judging valuation or financial health.

Over the past year, BMYMP's profit margin moved from 12.57% to 18.46% — a 46.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bristol-Myers Squibb Company PFD CONV 2's valuation or profitability profile.

Against Healthcare companies, BMYMP currently prints 18.46% for profit margin, while the sector average sits near 9.48%. That is roughly 94.7% above the sector mean. Large gaps often invite a closer look at Bristol-Myers Squibb Company PFD CONV 2's growth, margins, and balance sheet.

Profit Margin shows how effectively Bristol-Myers Squibb Company PFD CONV 2 converts resources into returns. At 18.46%, BMYMP may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 12.57% in the prior-year period — up 46.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BMYMP's profit margin (18.46%), review year-over-year change from 12.57%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.